# A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

> **NCT06001177** · PHASE2 · COMPLETED · sponsor: **Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA** · enrollment: 55 (actual)

## Conditions studied

- Celiac Disease
- Coeliac Disease

## Interventions

- **DRUG:** KAN-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06001177
- **Lead sponsor:** Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-13
- **Primary completion:** 2025-01-03
- **Final completion:** 2025-01-13
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001177, "A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06001177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*